CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Dabigatran etexilateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug708 Dabigatran etexilate + BI 1323495 Wiki 1.00
drug2111 Rosuvastatin Wiki 1.00
drug2112 Rosuvastatin + BI 1323495 Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D006333 Heart Failure NIH 0.38
D002318 Cardiovascular Diseases NIH 0.21

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0001635 Congestive heart failure HPO 0.38
HP:0001626 Abnormality of the cardiovascular system HPO 0.21

There is one clinical trial.

Clinical Trials


1 Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1323495 in Healthy Male Subjects (Open, Single-dose, Randomised, Two-period Crossover Design in Each Trial Part)

The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following oral administration.

NCT04257032 Healthy Drug: Rosuvastatin Drug: Rosuvastatin + BI 1323495 Drug: Dabigatran etexilate Drug: Dabigatran etexilate + BI 1323495

Primary Outcomes

Measure: Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

Time: up to 5 days

Measure: Maximum measured concentration of Rosuvastatin in plasma (Cmax)

Time: up to 5 days

Measure: Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

Time: up to 4 days

Measure: Maximum measured concentration of Dabigatran in plasma (Cmax)

Time: up to 4 days

Secondary Outcomes

Measure: Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Time: up to 5 days

Measure: Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Time: up to 4 days


No related HPO nodes (Using clinical trials)